Title21 buys cResults to expand quality operations software

By AI, Created 7:26 PM UTC, June 01, 2026, /AGP/ – Title21 Health Solutions has acquired cResults to add resource planning and scheduling tools to its life sciences quality platform. The deal aims to help biopharma, cell and gene therapy, and other regulated organizations reduce bottlenecks and improve delivery of critical therapies.

Why it matters: - Title21 Health Solutions is expanding beyond quality management into planning and scheduling tools for quality operations. - The combined platform is aimed at life sciences organizations that need to manage more products, sites, and regulatory demands without adding bottlenecks. - The deal is meant to connect quality systems with resource capacity and workload visibility. - Title21 is positioning itself as a single-source digital partner for regulated healthcare and life sciences organizations.

What happened: - Title21 Health Solutions announced it acquired cResults on June 2, 2026. - The acquisition adds cResults’ efficiency management, resource planning, and scheduling software to Title21’s portfolio. - Title21 serves biopharma, cell and gene therapy, and broader life sciences customers. - cResults was founded in 2005 and has nearly two decades of domain experience in life sciences operations software.

The details: - cResults’ flagship Smart-QX platforms are designed for quality operations planning and scheduling. - The platforms are intended to improve cycle time, on-time delivery, and resource efficiency. - Title21’s existing portfolio includes Quality Management Systems, cell and gene therapy orchestration platforms, and advanced analytics. - The integration is meant to cover the full lifecycle of quality operations, from manufacturing to compliance. - Title21 is targeting cellular therapy, pharmaceutical, biotech, and broader life sciences sectors. - Tony Pare, Title21 CEO, said clients had asked for smarter tools that connect with quality management systems and show real-time resource capacity and workload. - Pare said Smart-QX is deployed at some of the world’s leading life sciences organizations and that ROI from process and resource optimization is well documented. - Rafi Maslaton, founder and president of cResults, said the combined companies create a one-stop shop for digital planning, scheduling, and quality management across manufacturing and quality operations. - Title21 is an ARCHIMED portfolio company. - ARCHIMED is a healthcare-focused growth equity firm based in New York and Lyon, France. - Title21 says it has focused since 2001 on technology that helps healthcare and life sciences firms achieve compliance, gain efficiencies, and improve patient safety and care. - Title21’s website is title21.com. - cResults’ website is cresultsconsulting.com.

Between the lines: - The acquisition reflects a broader push in life sciences software toward integrated platforms rather than standalone tools. - Title21 appears to be betting that quality operations teams will value scheduling, compliance, and analytics in one system instead of stitching together multiple vendors. - The focus on resource optimization suggests the deal is aimed at operational pressure as much as at software consolidation.

What’s next: - Title21 will integrate Smart-QX capabilities into its existing quality and operations stack. - The combined platform is expected to support faster planning, better capacity visibility, and improved compliance workflows. - Title21 is signaling further growth around digital planning and quality operations in life sciences.

The bottom line: - Title21 is using the cResults acquisition to move deeper into the daily operating challenges of regulated life sciences manufacturing and quality teams.